表紙
市場調查報告書

鴉片類藥物疾病:到2028年的市場機會分析和預測

Opioid Use Disorder: Opportunity Analysis and Forecasts to 2028

出版商 GlobalData 商品編碼 953720
出版日期 內容資訊 英文 116 Pages
訂單完成後即時交付
價格
鴉片類藥物疾病:到2028年的市場機會分析和預測 Opioid Use Disorder: Opportunity Analysis and Forecasts to 2028
出版日期: 2020年07月30日內容資訊: 英文 116 Pages
簡介
鴉片類藥物是刺激大腦和神經系統中鴉片類藥物受體的合成或天然藥物,通常用於治療患有疼痛的患者。儘管按規定劑量服用不會上癮,但長期反複使用阿片類藥物可能會導致慢性神經系統疾病阿片類藥物使用障礙(OUD)。由於大腦適應長期使用鴉片類藥物,患者變得更加寬容,需要與原始劑量相似的更高劑量的鴉片類藥物來刺激中腦邊緣系統,並且患者繼續接受高劑量的鴉片類藥物。您將開始使用毒品。 OUD患者可分為沈迷於用於治療慢性疼痛症狀的醫學類鴉片類藥物和沈迷於海洛因和芬太尼等非醫學類阿片類藥物的患者。目前已批准了幾種OUD治療劑,並將其分類為合成類阿片受體激動劑(丁丙諾啡,美沙酮,嗎啡,醫學級海洛因)和阿片類拮抗劑(納曲酮)。預計全球八個主要國家(美國,加拿大,德國,奧地利,比利時,丹麥,瑞士,澳大利亞)的OUD治療市場將從2018年的16億美元增長到2028年的37億美元,此期間的複合年增長率為8.8%。到2028年,美國仍然是最大的市場,佔總銷售額的87.7%。

該報告調查了八個主要國家的OUD市場,並提供了諸如疾病概述,流行病學,治療方法,治療方法的研發和管道評估等信息。

內容

第1章內容

  • 圖表列表

第2章鴉片類藥物使用障礙概述

  • 丁丙諾啡修飾促進OUD市場增長
  • 經驗豐富的公司和初創公司競爭丁丙諾啡處方
  • 不受支持的環境需求比臨床需求更重要
  • 改革管線側重於後期管線,新MOA側重於早期管線
  • 醫生的想法

第3章簡介

第4章疾病概述

  • 病因與病理生理
    • 病因
    • 病理生理學
  • 分類或分級系統

第5章流行病學

  • 疾病背景
  • 風險因素和合併症
  • 世界和歷史趨勢
  • 預測調查方法
  • OUD流行病學預測(2018-2028)
  • 討論
    • 流行病學預測見解
    • 分析限制
    • 分析實力

第6章當前的治療選擇

  • 概述

第7章未滿足的需求和機會的評估

  • 概述
  • 消除訪問障礙
  • 新的行動機制
  • 改善治療指南

第8章研發策略

  • 概述
    • 藥物濫用可能性低
    • 新穎的作用機制
    • 緩釋製劑,可提高順應性
  • 臨床試驗設計
    • 終點
    • 試用期
    • 對照藥物
    • 患者人數

第9章管道評估

  • 概述
  • 早期的創新方法
  • 其他正在開發的藥物

第10章管道評估分析

第11章附錄

目錄
Product Code: GDHC114POA

Opioids are synthetic or natural agents that stimulate opioid receptors in the brain and nervous system. Opioids are often used to treat patients suffering from pain. When taken in the prescribed quantities, opioids do not generally lead to addiction. Opioid use disorder (OUD) is a chronic neurological disorder that is described as the consequences associated with repeated, compulsive use of opioid drugs, and prolonged self-administration of opioid drugs. As the brain adapts to a prolonged opioid use, the patient's tolerance increases, so a higher dose of opioid is needed to stimulate the mesolimbic system in the same way as the original dose, leading patients to use continued higher doses of the drug. There are two subsets of patients who suffer from OUD: patients who become addicted to medical opioids, which are used to treat chronic pain conditions, and patients who become addicted to non-medical opioids, such as heroin and fentanyl. There is no single cause of OUD, but rather a combination of genetic and environmental factors that influence the patient.

Currently, several drugs have been approved for the treatment of OUD, which can be split into two classes: synthetic opioid receptor agonists (buprenorphine, methadone, morphine, and medical-grade heroin) and opioid antagonists (naltrexone). Many of these drugs have been widely available for decades and are genericized across the markets covered in this report. Some reformulations that have been released more recently, and some are expected to launch during the forecast period, making them a market driver toward the end of the forecast period.

During the 10-year forecast period, the OUD market is expected to grow from $1.6B in 2018 to $3.7B in 2028 in the 8MM, which represents a CAGR of 8.8%. The US is expected to maintain its position as the market leader in 2028, with sales contributing 87.7% to the global market.

The main driver of growth over the forecast period will be the launch of new formulations of buprenorphine, particularly Indivior's Sublocade, which is already launched in the US, Canada, and Australia, as well as Camurus' Buvidal, which is already launched in Europe and Australia. Both are subcutaneous monthly forms of buprenorphine.

There are several drugs that will see their patents expire throughout the forecast period, the most high-profile being Indivior's Suboxone, which is a key barrier of growth in this market. Suboxone, the sublingual buprenorphine + naloxone combination, was the highest-selling drug with sales of $859M in 2018. However, its sales are expected to fall throughout the forecast period at a negative CAGR of 16.9%, due to generic erosion.

Key Questions Answered

  • How will the OUD market landscape in the 8MM (US, Canada, Germany, Austria, Belgium, Denmark, Switzerland, and Australia) change from 2018-2028?
  • What are the most promising late-stage pipeline drugs for OUD?
  • How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
  • What are the remaining unmet needs in OUD treatment management?
  • What drivers and barriers will affect OUD therapeutics sales in the 8MM over the forecast period?

Scope

  • Overview of OUD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
  • Topline OUD market revenue from 2018-2028. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
  • Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting OUD therapeutics sales in the 8MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global OUD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Global OUD market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the OUD therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Opioid Use Disorder: Executive Summary

  • 2.1 Reformulations of Buprenorphine Will Drive Growth in the OUD Market
  • 2.2 Experienced and New Players Go Head-to-Head with Buprenorphine Reformulations
  • 2.3 Environmental Unmet Needs of Greater Importance than Clinical Needs
  • 2.4 Late-Stage Pipeline Remains Focused on Reformulations, While Early Stage Pipeline Looks to Novel MOAs
  • 2.5 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
  • 4.2 Classification or Staging Systems

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
    • 5.4.1 Sources Used
    • 5.4.2 Forecast Assumptions and Methods
    • 5.4.3 Forecast Assumptions and Methods: 12-Month Total Prevalent Cases of OUD
    • 5.4.4 Forecast Assumptions and Methods: 12-Month Diagnosed Prevalent Cases of OUD
    • 5.4.5 Forecast Assumptions and Methods: 12-Month Total and Diagnosed Prevalent Cases of OUD by Severity
    • 5.4.6 Sources Not Used
  • 5.5 Epidemiological Forecast for OUD (2018-2028)
    • 5.5.1 12-Month Total Prevalent Cases of OUD
    • 5.5.2 Age-Specific 12-month Total Prevalent Cases of OUD
    • 5.5.3 Sex-Specific 12-Month Total Prevalent Cases of OUD
    • 5.5.4 12-Month Total Prevalent Cases of OUD by Severity
    • 5.5.5 12-Month Diagnosed Prevalent Cases of OUD
    • 5.5.6 Age-Specific 12-Month Diagnosed Prevalent Cases of OUD
    • 5.5.7 Sex-Specific 12-Month Diagnosed Prevalent Cases of OUD
    • 5.5.8 12-month Diagnosed Prevalent Cases of OUD by Severity
  • 5.6 Discussion
    • 5.6.1 Epidemiological Forecast Insight
    • 5.6.2 Limitations of Analysis
    • 5.6.3 Strengths of Analysis

6 Current Treatment Options

  • 6.1 Overview

7 Unmet Needs and Opportunity Assessment

  • 7.1 Overview
  • 7.2 Removal of Access Barriers
  • 7.3 Novel Mechanisms of Action
  • 7.4 Improved Treatment Guidelines

8 R&D Strategies

  • 8.1 Overview
    • 8.1.1 Drug Formulations That Have Less Potential for Abuse
    • 8.1.2 Novel Mechanisms of Action
    • 8.1.3 Extended-Release Formulations That Improve Compliance
  • 8.2 Clinical Trials Design
    • 8.2.1 Endpoints
    • 8.2.2 Trial Duration
    • 8.2.3 Comparator Arms
    • 8.2.4 Patient Population

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Innovative Early Stage Approaches
  • 9.3 Other Drugs in Development

10 Pipeline Valuation Analysis

11 Appendix

List of Tables

  • Table 1: Opioid Use Disorder: Key Metrics in the 8MM
  • Table 2: Symptoms of Opioid Use Disorder
  • Table 3: Long Term Psychological Impacts of Opioid Use Disorder
  • Table 4: DSM-5 Diagnostic Criteria for Opioid Use Disorder
  • Table 5: Risk Factors a

List of Figures

  • Figure 1: Global Sales Forecast by Country for Opioid Use Disorder, 2018 and 2028
  • Figure 2: Competitive Assessment of the Pipeline Drugs Benchmarked Against the SOC, Suboxone
  • Figure 3: The Impact of Opioid Use Disorder on Brain Function
  • Fi